Weekly analog of GLP-2, a hormone that promotes growth and absorptive capacity of the intestine. Being investigated in short bowel syndrome with intestinal failure.
Regulatory status
In clinical trials
Family
Long-acting GLP-2 analog
Scientific evidence
Moderate
Number of findings
1
Where it acts
Digestion and weight
Also known as
apraglutide, FE 203799
Regulatory status
FDA (US): Not approved (the company is conducting a confirmatory phase 3 trial after the STARS trial).
EMA (EU): Not approved.
Dose
There is no established dose in humans. In trials it has been given subcutaneously once a week (5 or 10 mg in the phase 2 trial).
Safety
In the phase 2 trial: increased urine output, reduced stoma output, stoma complications, reduced thirst, and edema, generally mild or moderate. Use only in clinical trials or research, under medical supervision; buying it is not recommended.
Effect by goal · level of evidence
Fluid absorption in short bowel
increasesLowRCT (AA)in people
+~750 mL/day
Phase 2 crossover trial in 8 adults with short bowel: 4 weeks of weekly apraglutide increased urine output (a sign of greater intestinal absorption) by about 714–795 mL/day vs placebo.
Activates the GLP-2 receptor in the intestine. This makes the villi grow and improves intestinal blood flow, so that more fluids and nutrients are absorbed. The goal is to reduce the intravenous nutrition and hydration these patients need.
What the evidence says
In people
Fluid absorption in short bowel syndrome. Phase 2 crossover trial in 8 adults with short bowel syndrome: 4 weeks of weekly apraglutide increased urine output (a sign of greater intestinal absorption) by about 714–795 mL/day vs placebo. PubMed 34287970